AbbVie HCV drugs show high cure rate in another late-stage study
This article was originally published in Scrip
AbbVie’s hepatitis C drug regimen showed a 96% cure rate in a late-stage trial of chronically infected patients. The top line results are from the second of six studies by the company conducted to win US and European approval.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.